rule
HAS_LYMPHOCYTES_CELLS_PER_MM3_OF_AT_LEAST_X
HAS_HLA_TYPE_X
PD_L1_SCORE_TPS_OF_AT_MOST_X
HAS_PREVIOUSLY_PARTICIPATED_IN_CURRENT_TRIAL
HAS_HAD_COMBINED_TREATMENT_NAMES_X_WITHIN_Y_WEEKS
HAS_UNRESECTABLE_STAGE_III_CANCER
HAS_PHOSPHORUS_ULN_OF_AT_MOST_X
HAS_HISTORY_OF_SECOND_MALIGNANCY
HAS_RECEIVED_MEDICATION_INDUCING_CYP_X_WITHIN_Y_WEEKS
HAS_PROGRESSIVE_DISEASE_FOLLOWING_NAME_X_TREATMENT
HAS_CANCER_OF_UNKNOWN_PRIMARY_AND_TYPE_X
HAS_POTENTIAL_HYPOKALEMIA
HAS_POTENTIAL_HYPOMAGNESEMIA
HAS_POTENTIAL_HYPOCALCEMIA
MUTATION_IN_GENE_X_IN_EXON_Y_TO_EXON_Z
HAS_HAD_PARTIAL_RESECTION
MOLECULAR_TEST_MUST_HAVE_BEEN_DONE_FOR_PROMOTER_OF_GENE_X
HAS_HAD_RESECTION_WITHIN_X_WEEKS
HAS_PROGRESSIVE_DISEASE_FOLLOWING_CATEGORY_X_TREATMENT_OF_TYPES_Y_AND_AT_LEAST_Z_CYCLES
HAS_JTC_OF_AT_LEAST_X
HAS_SECONDARY_GLIOBLASTOMA
HAS_MRI_SCAN_DOCUMENTING_STABLE_DISEASE
HAS_EXTRACRANIAL_METASTASES
HAS_INTOLERANCE_TO_TAXANE
HAS_EVIDENCE_OF_CNS_HEMORRHAGE_BY_MRI
HAS_HAD_COMPLETE_RESECTION
MEETS_SPECIFIC_REQUIREMENTS_REGARDING_BIOPSY
PD_L1_STATUS_MUST_BE_AVAILABLE
HAS_LEFT_SIDED_COLORECTAL_TUMOR
HAS_LUNG_METASTASES
HAS_HAD_TREATMENT_NAME_X_WITHIN_Y_WEEKS
HAS_HAD_COMBINED_TREATMENT_NAMES_X_AND_BETWEEN_Y_AND_Z_CYCLES
HAS_HAD_FIRST_LINE_CATEGORY_X_TREATMENT_OF_TYPES_Y
HAS_HAD_ADJUVANT_CATEGORY_X_TREATMENT
HAS_PROGRESSIVE_DISEASE_FOLLOWING_CATEGORY_X_TREATMENT_OF_TYPES_Y_AND_AT_LEAST_Z_WEEKS
PROTEIN_X_IS_WILD_TYPE_BY_IHC
HAS_URINE_PROTEIN_TO_CREATININE_RATIO_MG_PER_MG_OF_AT_MOST_X
HAS_THYROXINE_WITHIN_INSTITUTIONAL_NORMAL_LIMITS
HAS_KNOWN_CYTOMEGALOVIRUS_INFECTION
HAS_KNOWN_TUBERCULOSIS_INFECTION
CURRENTLY_GETS_MEDICATION_SUBSTRATE_OF_BCRP
HAS_ANY_COMPLICATION
HAS_LEUKOCYTES_ABS_LLN_OF_AT_LEAST_X
HAS_SOLID_PRIMARY_TUMOR_INCLUDING_LYMPHOMA
MEETS_SPECIFIC_CRITERIA_REGARDING_BRAIN_METASTASES
MEETS_SPECIFIC_CRITERIA_REGARDING_LIVER_METASTASES
HAS_PRESENCE_OF_LESIONS_IN_AT_LEAST_X_SITES
HAS_INJECTION_AMENABLE_LESION
IS_ELIGIBLE_FOR_TREATMENT_LINES_X
HAS_HAD_INTRATUMORAL_INJECTION_TREATMENT
HAS_PT_WITHIN_INSTITUTIONAL_NORMAL_LIMITS
HAS_APTT_WITHIN_INSTITUTIONAL_NORMAL_LIMITS
HAS_NON_SQUAMOUS_NSCLC
HAS_KNOWN_HEPATITIS_A_INFECTION
CURRENTLY_GETS_MEDICATION_INHIBITING_OR_INDUCING_ANY_CYP
HAS_HAD_CATEGORY_X_TREATMENT_OF_TYPE_Y_AS_MOST_RECENT_LINE
HAS_UGT1A1_HAPLOTYPE_X
HAS_HOMOZYGOUS_DPYD_DEFICIENCY
HAS_UNRESECTABLE_PERITONEAL_METASTASES
NON_EXPRESSION_OF_GENE_X
HAS_HAD_CYTOREDUCTIVE_SURGERY
HAS_EXTENSIVE_SYSTEMIC_METASTASES_PREDOMINANTLY_DETERMINING_PROGNOSIS
HAS_HAD_SYSTEMIC_THERAPY_WITH_ANY_INTENT_X_WITHIN_Y_MONTHS
HAS_HAD_SYSTEMIC_THERAPY_WITH_ANY_INTENT_X
HAS_INHERITED_PREDISPOSITION_TO_BLEEDING_OR_THROMBOSIS
MOLECULAR_TEST_MUST_HAVE_BEEN_DONE_FOR_GENE_X
HAS_POTENTIAL_UNCONTROLLED_TUMOR_RELATED_PAIN
HAS_RESTING_HEART_RATE_BETWEEN_X_AND_Y
HAS_HAD_LOCAL_HEPATIC_THERAPY_WITHIN_X_WEEKS
HAS_PHOSPHORUS_MMOL_PER_L_OF_AT_MOST_X
HAS_FAMILY_HISTORY_OF_LONG_QT_SYNDROME
HAS_IRRADIATION_AMENABLE_LESION
HAS_MEASURED_CREATININE_CLEARANCE_OF_AT_LEAST_X
CURRENTLY_GETS_HERBAL_MEDICATION
HAS_HAD_ANY_CANCER_TREATMENT_IGNORING_CATEGORY_X
HAS_POTENTIAL_RESPIRATORY_COMPROMISE
PD_L1_SCORE_TPS_OF_AT_LEAST_X
PD_L1_SCORE_IC_OF_AT_LEAST_X
ACTIVATING_MUTATION_IN_GENE_X_EXCLUDING_CODONS_Y
HAS_KNOWN_SCLC_TRANSFORMATION
HAS_HAD_OBJECTIVE_CLINICAL_BENEFIT_FOLLOWING_NAME_X_TREATMENT
HAS_ANTI_HLA_ANTIBODIES_AGAINST_PDC_LINE
HAS_RECEIVED_PLATINUM_BASED_DOUBLET
HAS_HAD_RADIOTHERAPY_TO_BODY_LOCATION_X
HAS_EGFR_PACC_MUTATION
HAS_HAD_SYSTEMIC_THERAPY_WITHIN_X_MONTHS
HAS_NOT_RECEIVED_ANY_CANCER_TREATMENT_WITHIN_X_MONTHS
HAS_HAD_TREATMENT_WITH_ANY_DRUG_X_WITHIN_Y_WEEKS
HAS_PROGRESSIVE_DISEASE_FOLLOWING_TREATMENT_WITH_ANY_DRUG_X
HAS_HISTORY_OF_THROMBOEMBOLIC_EVENT_WITHIN_X_MONTHS
HAS_HAD_BRAIN_RADIATION_THERAPY
HAS_POTENTIAL_CONTRAINDICATION_FOR_STEREOTACTIC_RADIOSURGERY
HAS_POTENTIAL_SYMPTOMATIC_HYPERCALCEMIA